A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Relapsed or Refractory Hematological Malignancies Clinical Trial

Official title: A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies

Status Recruiting

Clinical Trial Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.

Clinical Trial Description

This is a single arm, open-label, single-center study to determine the safety and efficacy of CNCT19 in adult patients with r/r B cell Malignancies. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total duration of the study is 2 years from CNCT19 cell infusion. ;

Related Conditions & MeSH terms

• Neoplasms
• Relapsed or Refractory Hematological Malignancies

• NCT number: NCT04011293
• Study type: Interventional
• Source: Shandong University
• Contact: Chuanli Zhao, Dr.
• Phone: ?+86 185 6008 7009?
• Email: chuanlizhao@163.com
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 2019
• Completion date: April 2022